Catalyst Repository | Salarius Pharmaceuticals Inc. Common Stock

Salarius Pharmaceuticals Inc. Common Stock

(NASDAQ:SLRX)

Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

SLRX Overview

None
Sector
Health Care
Industry
Major Pharmaceuticals

Previous Close
$1.1500
Previous Close Volume
32619